從孕前開始連續抗病毒治療預防圍產期乙型肝炎病毒傳播的

StephenW

Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus
Xingfei Pan  1 , Jingsi Chen  2   3   4 , Liyang Zhou  1 , Xueting Ou  1 , Fang He  4   5 , Yifen Liu  4   5 , Shuo Zheng  1 , Haibin Wang  6 , Bin Cao  6 , Zhijian Wang  7 , Huishu Liu  8 , Guocheng Liu  9 , Zhenyu Huang  10 , Guanxin Shen  11 , Shiliang Liu  12   13 , Dunjin Chen  14   15   16
Affiliations

    PMID: 32788743 DOI: 10.1038/s41598-020-70644-4

Abstract

Few studies were conducted to assess safety and efficacy of continuous antiviral therapy administrated from preconception. In the present study, 136 eligible women with chronic HBV infection were recruited, and assigned to active chronic hepatitis B (CHB) (Group A, B or C) or chronic HBV carrier (Group D). Antiviral therapy was administrated in preconception (Group A), in early (Group B) or late pregnancy (Group C and Group D). Immunoprophylaxis was administrated to all infants. Mothers' HBV status and ALT were assessed at delivery and 7 months postpartum. Offspring's HBV status was examined at 7 months old. Group A women showed low HBV DNA level and normal ALT throughout pregnancy. All women at delivery had an HBV DNA level of less than 106 IU/ml, but the proportion of patients with lower HBV DNA level in Group A was higher than any of other three groups (P < 0.05). No differences in obstetrical complications were found among the four groups. None of infants who completed follow-up showed positive HBsAg at age of 7 months. Congenital malformation and infant growth indicators were similar among study cohorts. Continuous antiviral therapy from preconception to entire pregnancy is effective and safe for active CHB mothers and their infants.

StephenW

從孕前開始連續抗病毒治療預防圍產期乙型肝炎病毒傳播的療效和安全性
潘興飛1，陳靜思2 3 4，周麗陽1，歐雪婷1，方禾4 5，劉亦芬4 5，朔正1，王海濱6，曹斌6，王志堅7，劉慧書8，劉國成9，黃振宇10，沉冠新11，劉世良12 13，陳敦津14 15 16
隸屬關係

    PMID：32788743 DOI：10.1038 / s41598-020-70644-4

抽象

很少進行研究來評估從孕前開始進行連續抗病毒治療的安全性和有效性。在本研究中，招募了136名符合條件的慢性HBV感染婦女，並分配給活動性慢性乙型肝炎（CHB）（A，B或C組）或慢性HBV攜帶者（D組）。在孕前（A組），妊娠早期（B組）或妊娠晚期（C組和D組）進行抗病毒治療。對所有嬰兒均進行了免疫預防。在分娩時和產後7個月評估母親的HBV狀況和ALT。在7個月大時檢查後代的HBV狀況。 A組婦女在整個懷孕期間均表現出較低的HBV DNA水平和正常的ALT。所有分娩婦女的HBV DNA水平均低於106 IU / ml，但A組中HBV DNA水平較低的患者比例高於其他三組（P <0.05）。四組之間的產科並發症無差異。完成隨訪的嬰兒中，沒有一個在7個月大時出現HBsAg陽性。在研究隊列中，先天性畸形和嬰兒生長指標相似。從懷孕前到整個懷孕期間持續進行抗病毒治療對於活躍的CHB母親及其嬰兒都是有效和安全的。

StephenW

https://www.nature.com/articles/s41598-020-70644-4.pdf